Patient group: Thirty-six male or female mixed-breed dogs with experimentally induced myocardial infarction. Potential study animals underwent electrical stimulation to assess for a predisposition to develop arrhythmias; only unresponsive animals were selected for the study as they were considered 'low risk' for the development of subsequent lethal ischaemic arrhythmias. Of the animals deemed 'low risk' and therefore entered into the investigation, 
Summary of evidence
Paper 1: Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration (MMVD) 10 Patient group: Eight client-owned small breed dogs (<15 kg) with CHF due to MMVD. Four dogs received placebo and four received pimobendan. Study type: Prospective double-blind randomised placebo-controlled crossover study. Outcomes: Two weeks after administration of the placebo or pimobendan, average heart rate, type and incidence of arrhythmia, determined using 24-hour Holter ECG analysis, was compared to baseline data. A quality of life questionnaire was completed and sleeping respiration rates recorded by owners at baseline and two weeks after drug administration.
Key results: Quality of life scores calculated using owner questionnaires were significantly improved following administration of both placebo (P=0.021) and pimobendan (P<0.001). No significant differences were identified in the type or incidence of arrhythmias. Average heart rate in dogs that received pimobendan was significantly lower
Clinical scenario
Pimobendan is a positive inotrope and balanced vasodilator via its actions as a calcium sensitiser and phosphodiesterase III inhibitor, respectively. 1 There is strong evidence for its use in the treatment of dogs with congestive heart failure (CHF), with multiple clinical trials demonstrating a resultant increase in survival time. [2] [3] [4] [5] However, the use of pimobendan for treatment of heart disease in people has been associated with increased risk of arrhythmias. 6 This effect is attributed to the racemic nature of pimobendan resulting in D and L chiral enantiomers, with the L-optical isomer having a significantly greater calcium sensitising effect. [7] [8] [9] There is limited data available regarding any effect of treatment with pimobendan on the risk of arrhythmias in dogs. The aim of this article is to analyse the available data to determine whether evidenced-based conclusions can be drawn.
The question
In A significant number of dobermans with preclinical DCM develop arrhythmias, which may result in sudden death. Dogs with arrhythmias before treatment were noted in the study but not excluded. The study protocol was amended during recruitment to include hypothyroid dogs. Antiarrhythmic therapy was permitted if dogs developed ventricular arrhythmias during the trial, and these dogs remained in the study. Physical examinations were only performed every six months.
Paper 5: Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: EPIC study (12) Patient group: Three-hundred-and-sixty client-owned dogs with MMVD with left atrial-to-aortic ratio over 1.6, normalised left ventricular internal diameter in diastole over 1.7, and vertebral heart sum over 10.5. Study type: Prospective, randomised, placebo-controlled, double blinded, multicentre clinical trial. Outcomes: Time to a composite of the onset of CHF, cardiac-related death, or euthanasia. Key results: Median time to primary endpoint was 1228 days in the pimobendan group and 277 days in the placebo group (P=0.0038). Hazard ratio for pimobendan group was 0.64 compared with the placebo group (P=0.0002). There was no difference in adverse events between treatment groups (P=0.82).
Paper 3: Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study 4 Patient group: Two-hundred-and-sixty client-owned dogs recruited from 28 centres in Europe, Canada, and Australia were included in the study. Study type: Prospective, multicentre, single-blinded, positive-controlled study. Outcomes: The primary end point was a composite of cardiac death, euthanasia as a result of heart failure or treatment failure. The onset of arrhythmias was assessed at one, three, six, nine, 12, 15 and 18 months using ECG. Key results: The time to end point was 267 days for pimobendan and 140 days for benazepril (hazard ratio 0.688, 95 per cent confidence intervals [CI] 0.516 to 0.916, P=0.0099). This benefit persisted after adjustment for baseline variables. There was no difference in the onset of arrhythmias between the two treatment groups. Study weaknesses: Only dogs with CHF as a result of MMVD were included. The primary end point was a composite of three possible outcomes (only two resulting in death), the third (treatment failure) lacks the incontrovertible nature of death and is yet to be validated as a good surrogate for survival; however, the study outlines what was predefined as treatment failure. Treatment failure was used as a surrogate in 20 pimobendan and 27 benazepril dogs. Lack of double blinding meant that owners were aware of the medication used. Defining the cause of death as cardiac or non-cardiac in an aging population is problematic due to comorbidity. Study population had a larger proportion of Cavalier King Charles spaniels and dachshunds than previous large trials. The primary parameter assessed was treatment efficacy; therefore, the study was not designed specifically to detect arrhythmias, although ECGs were performed at multiple time points throughout the study and onset of arrhythmias recorded.
Paper 4:
Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in doberman pinschers with preclinical dilated cardiomyopathy (DCM) (The Protect Study) 5 Patient group: Seventy-six client-owned dobermans at 10 centres in the UK and North America were included in the study. Study type: Randomised, double blinded, placebo-controlled, parallel-group multi-10 dogs received 200 µg/kg/hour of milrinone administered via constant rate infusion for six hours, nine received 300 µg/kg pimobendan administered intravenously over 20 minutes, and 12 received a placebo solution (six received 50 per cent polyethylene glycol-200 in 0.9 per cent saline and six received just 0.9 per cent saline). Study type: Prospective, randomised, placebo-controlled study. Outcomes: Electrophysiological testing and programmed ventricular stimulation were undertaken at 30 minutes after pimobendan and vehicle administration and two hours after milrinone administration to allow for the development of equivalent ionotropic responses in the two groups. The parameters measured included: ECG intervals, minimum voltage required to produce a conducted ventricular impulse, and incidence of ischaemic mortality at 24 hours following development of posterolateral myocardial ischaemia. Key results: Administration of pimobendan after a myocardial infarction event resulted in significant shortening of PR (P=0.01) and QTc intervals (P=0.05), as well as generalised shortening of refractory periods (P values ranged from 0.01 to 0.04 depending on the exact measurement site). All placebo-and pimobendan-treated animals remained unresponsive to programmed ventricular stimulation at all time points. However, one pimobendan-treated animal was excluded due to the postdrug appearance of spontaneous ventricular ectopy. No spontaneous or provoked ventricular ectopy was observed in the remaining pimobendantreated animals. Pimobendan administration resulted in a significant increase in the incidence of sudden ischaemic ventricular fibrillation; however, incidence of ischaemic mortality at 24 hours was not significant (P=0.083) when compared to the low risk control group. Study weaknesses: This study was carried out on dogs with experimentally induced myocardial infarction, a condition rarely seen in dogs. Furthermore, a dose of 300 µg/ kg pimobendan administered intravenously over 20 minutes and a 200 µg/kg/hour dose of milrinone administered via continuous intravenous infusion for six hours were used. These regimes were selected because of their ability to produce a significant and sustained increase in cardiac inotropic status; there was no attempt to recreate therapeutic dosing schedules, 0.15 mg pimobendan/ kg bodyweight injectable solution, used for clinical canine heart failure patients.
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animals treated with pimobendan. While this study is a useful starting point the small study population (n=8) and the inclusion of only small-breed dogs with stable, medically controlled CHF limits the generalisation of its findings. The merits of paper 2 were the larger study population combined with the assessment of electrophysiological parameters such as the voltage required to produce a ventricular impulse as an indicator of arrhythmic properties. However, the study was conducted on dogs with experimentally induced myocardial infarction, a proarrhythmic model, making it impossible to draw accurate comparisons to non-ischaemic conditions such as MMVD. Furthermore, dogs in this study were administered pimobendan doses chosen to induce increased cardiac inotropic status. Therefore, it can be concluded that the finding of increased ventricular fibrillation in this study is not clinically relevant. The QUEST, PROTECT and both EPIC studies were the largest and best designed. While none specifically aimed to collect data on occurrence of arrhythmias, the QUEST study found no increase in the onset of arrhythmia and the PROTECT study found no increased risk of proarrhythmia. Disappointingly, neither EPIC study specifically reports arrhythmias as an adverse event; however, the first does report no overall difference in adverse events between the two study groups.
The studies varied in quality and strength of evidence. Only two studies specifically investigated arrhythmia, one very small and the other carried out in an experimentally induced proarrhythmic disease model using non-therapeutic doses of pimobendan. The much large EPIC study reported equal incidence of adverse events while the PRO-TECT and QUEST study specifically noted no increase in arrhythmias in patient groups treated with pimobendan. These studies were well designed and included a large and varied population of dogs, they therefore provide good quality evidence to support our clinical bottom line.
Bottom line
To date there is no evidence to suggest pimobendan is associated with an increased risk of arrhythmias in dogs.
